Results 101 to 110 of about 4,732,777 (361)

Triple Negative Breast Cancer Patients Treated with Radiation Therapy: Improvement in Survival and Local Control With Adjuvant Chemotherapy Compared To Neoadjuvant Chemotherapy – A Hypothesis Generating Report [PDF]

, 2021
Mary R Nittala, Satyaseelan Packianathan, Gary Shultz, Paul Roberts, Eswar Mundra, Divyang Mehta, Maria L. Smith, William C. Woods, Lacey Weatherall, Shawn McKinney, Barbara S. Craft, Grace G. Shumaker, Dennis P. Morgan, Scott Berry, Srinivasan Vijayakumar   +14 more
openalex   +1 more source

CD20+FCRL4+ B Cells Activate CD8+ T Cells via MHC‐I Restriction in Nasopharyngeal Carcinoma Anti‐Tumor Immunity

Advanced Science, EarlyView.
CD20⁺FCRL4⁺ B cells in nasopharyngeal carcinoma actively cross‐present exogenous tumor antigens via MHC‐I, enhancing CD8⁺ T‐cell activation, memory formation, and cytotoxicity. IFNγ‐driven WDFY4 upregulation facilitates this process. These findings reveal an unconventional B‐cell–mediated antitumor mechanism and indicate potential relevance to ...
Benjian Zhang, Xiaotian Yuan, Kelei Gao, Bo You, Yaxuan Wang, Lai Meng, Zirong Chen, Shaobing Xie, Yunqing Liu, Zijian Dong, Shumin Xie, Ruohao Fan, Fengjun Wang, Junyi Zhang, Zhihai Xie, Yongzhen Mo, Hua Zhang, Weihong Jiang   +17 more
wiley   +1 more source

Long‐Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma

Cancer Medicine
Introduction This study aimed to compare the long‐term effects of neoadjuvant therapy and upfront surgery on overall survival (OS) and progression‐free survival (PFS) in patients with resectable pancreatic ductal adenocarcinoma (PDAC).
Kyung In Shin, Min Sung Yoon, Jee Hoon Kim, Won Joon Jang, Galam Leem, Jung Hyun Jo, Moon Jae Chung, Jeong Youp Park, Seung Woo Park, Ho Kyoung Hwang, Chang Moo Kang, Seung‐seob Kim, Mi‐Suk Park, Hee Seung Lee, Seungmin Bang   +14 more
doaj   +1 more source

Post-Neoadjuvant Therapy [PDF]

Breast Care, 2019
Michael Untch, Andreas Schneeweiss, David Krug, Thorsten Kühn, Sibylle Loibl   +4 more
openaire   +2 more sources

Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.

JAMA Oncology, 2019
Importance Patients with locally advanced pancreatic cancer have historically poor outcomes. Evaluation of a total neoadjuvant approach is warranted. Objective To evaluate the margin-negative (R0) resection rate of neoadjuvant FOLFIRINOX (fluorouracil,
Janet E. Murphy, J. Wo, D. Ryan, Jeffrey W. Clark, Wenqing Jiang, B. Yeap, L. Drapek, L. Ly, Christian V. Baglini, L. Blaszkowsky, C. Ferrone, A. Parikh, C. Weekes, R. Nipp, E. Kwak, Jill N. Allen, R. Corcoran, D. Ting, J. Faris, A. Zhu, L. Goyal, D. Berger, M. Qadan, K. Lillemoe, Nilesh P. Talele, R. Jain, T. Delaney, D. Duda, Y. Boucher, C. F. Fernandez-Del Castillo, T. Hong   +30 more
semanticscholar   +1 more source

Advanced Human Immune Cell‐Organoid Co‐Cultures for Functional Testing of Cancer Nanovaccines

Advanced Science, EarlyView.
Pancreatic ductal adenocarcinoma remains difficult to treat. We establish an organoid–immune co‐culture using patient‐derived organoids and matched T‐cells to assess cancer vaccines. A mesothelin‐targeted nanovaccine activates antigen‐specific T‐cells, increases IFN‐γ, and targets MSLN+ organoids.
Nathalia Ferreira, David Agorku, Andre Rosa, Julia Roosz, Lena Christ, Nicole Anderle, Ajinkya Kulkarni, Abir Hussein, Sana S. Sayedipour, Omar F. Luna, Tobias Legler, Philipp Ströbel, Fernando Albericio, Luis Cruz, Phillipp Beckhove, Peter Loskill, Frauke Alves, M. Andrea Markus, Fernanda Ramos‐Gomes   +18 more
wiley   +1 more source

Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection.

Annals of Surgery, 2019
OBJECTIVE The aim of the study was to identify the survival of patients with locally advanced pancreatic cancer (LAPC) and assess the effect of surgical resection after neoadjuvant therapy on patient outcomes.
G. Gemenetzis, V. Groot, A. Blair, D. Laheru, Lei Zheng, A. Narang, E. Fishman, R. Hruban, Jun Yu, R. Burkhart, J. Cameron, M. Weiss, elliot k fishman, Jin He   +13 more
semanticscholar   +1 more source

PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma

Advanced Science, EarlyView.
Integrated scRNA‐seq, scTCR‐seq analysis, and functional assays identify PRDM1+ malignant epithelial cells with hyper lipid peroxidation characteristics that demonstrate reduced responsiveness to the nICRT treatment. Principal factor PRDM1 activates cysteine metabolism genes to modulate lipid peroxidation (an intrinsic cellular pathway related to ...
Dijian Shen, Rui Li, Yong She, Xuefei Liu, Yuanyang Huang, Yongling Ji, Keying Chen, Zhengbo Song, Runzhe Chen, Xuan Li, Qi Zhao, Qixun Chen, Ming Chen   +12 more
wiley   +1 more source

NEOADJUVANT THERAPY FOR PROSTATIC CANCER

The Japanese Journal of Urology, 1993
Neoadjuvant therapy for prostatic cancer might be important to increase cure rates of the disease and preservability of the organs. There were 43 cases in a period of 1975-1990 in which total prostatectomy were performed after neoadjuvant therapy. According to the clinical stage, there were 14 cases in B, 23 in C, 4 in D1 and 2 in D2.
O, Maeda, S, Saiki, T, Kinouchi, M, Kuroda, T, Miki, M, Usami, T, Kotake   +6 more
openaire   +3 more sources

Neoadjuvant therapy for gastrointestinal stromal tumors: A propensity score‐weighted analysis [PDF]

, 2021
Kathryn E. Marqueen, Erin Moshier, Michael Buckstein, Celina Ang   +3 more
openalex   +1 more source